The €50,000 Longevity Clinic and the €200 Blood Test and What Actually Predicts Your Heart's Next Decade
Hilaryano Ferreira is a cardiologist and the founder of Aethera Health, an EU-licensed telehealth platform delivering physician-led online care across Europe. He works in cardiology and co-authored early peer-reviewed research on using AI to automate remote cardiac monitoring.
Longevity has become the most expensive word in wellness. In 2026, concierge and "boutique longevity" programmes charge between €1,500 and €100,000 a year for deep blood panels, full-body scans, biological-age reports and a plan built around supplements, sleep and cold water. The clients are successful people who have decided that their health deserves the same rigour as their business. That instinct is right. The market that has grown up to serve it is not always.
I am a cardiologist, and cardiovascular disease is still the thing most likely to end the life of a high-performing man or woman in Europe. So here is the question I would put to anyone about to spend serious money on their longevity: Of everything on that glossy menu, what actually predicts whether your heart will still be working properly in ten years? The answer is shorter than the brochure, and much of it costs about as much as a good lunch.
What changed in cardiology in 2026?
Quietly, a great deal. The 2026 dyslipidemia guideline from the American College of Cardiology and the American Heart Association, the first full rewrite in years, did three things that matter to a reader of this magazine. It recommended that every adult have lipoprotein(a), or Lp(a), measured at least once in their lifetime. It recognised apolipoprotein B (ApoB) as a more accurate measure of the particles that actually cause atherosclerosis. And it upgraded coronary artery calcium scoring to a Class 1 recommendation for deciding who needs treatment and who does not. In plain terms, the tests that the best preventive cardiologists have been using for a decade are now official, and none of them requires a €50,000 membership.
Which five numbers predict your heart's next decade?
Apolipoprotein B. Standard cholesterol reports measure the fat carried in your blood. ApoB counts the particles carrying it, and it is the particles that lodge in the artery wall. Two people with identical "normal" low-density lipoprotein (LDL) levels can have very different ApoB levels, and it is the one with the higher count who is at risk. If your last panel did not include it, your risk was estimated with the wrong instrument.
Lipoprotein(a). Roughly one adult in five carries a high level of this genetically determined particle, which raises the risk of heart attack and aortic valve disease independently of everything else. It barely changes with diet or exercise, which is exactly why it is worth knowing: It changes how aggressively everything else should be managed. One measurement, once in a lifetime, and most people have never had it.
Coronary artery calcium score. A computed tomography (CT) scan lasting a few minutes, requiring no contrast or fasting, counts the calcified plaque already in your coronary arteries. A score of zero in your forties or fifties is one of the most reassuring results in medicine; a high score in someone who "feels fine" is the single most common reason a preventive plan changes overnight. It is now the guideline's preferred tie-breaker when the risk calculators are uncertain, which, for fit and successful people in midlife, is most of the time.
Blood pressure, measured at home, not in a clinic. The number taken in a hurry at an executive medical is the least useful blood pressure you will ever record. Two weeks of morning and evening readings on a validated cuff tell the truth, and hypertension remains the largest single modifiable cause of stroke and heart failure worldwide.
Cardiorespiratory fitness. Among more than 120,000 adults followed by the Cleveland Clinic, the least fit had roughly five times the death rate of the most fit, and the benefit kept rising with every step up in fitness, with no ceiling. Maximal oxygen uptake (VO₂ max) is the cleanest measure, and a wearable's estimate is good enough to start with. This is the number the longevity industry gets right, and the one most people in leadership roles neglect first.
Add glycated haemoglobin (HbA1c) and a waist measurement, and you have the whole panel. The total cost in most European cities, when done privately, is a few hundred euros, including the calcium scan.
What does the longevity industry sell that the evidence does not support?
Biological-age reports are compelling to read and, so far, poor at changing outcomes; no major cardiovascular guideline uses them. Full-body magnetic resonance imaging (MRI) in people without symptoms finds many things, most of which are harmless and some of which lead to a year of anxious follow-up. Supplement stacks built on animal studies rarely survive contact with a human trial. None of this is fraud. It is enthusiasm running ahead of evidence, sold to people who can afford enthusiasm. The problem is not the spending. It is that the expensive items crowd out the cheap ones that actually move the risk.
There is a useful exception worth naming. The glucagon-like peptide-1 (GLP-1) medicines that most people know as weight-loss drugs cut major cardiovascular events by 20% in adults with overweight or obesity and existing heart disease in the SELECT trial, without diabetes. That is a cardiovascular result, not a cosmetic one, and it belongs in a serious conversation about prevention for the right patient, prescribed and monitored by a physician rather than bought online.
Why do successful people get worse preventive care, not better?
Because they buy in silos. A concierge physician, a longevity clinic, a wearable subscription and an annual executive medical in three different countries produce four reports that nobody reconciles. The single most valuable thing in preventive cardiology is not a test. It is one physician who holds every number, knows your family history and your travel schedule, and adjusts the plan as the numbers move. Brainz has explored why timing is the new longevity, and the same principle applies to the heart: It is not the volume of testing that protects you, but doing the right measurements early and acting on them in sequence.
Technology helps only when it serves that physician rather than replacing them. Artificial intelligence (AI) is very good at reading a wearable's data, structuring a history and flagging what has changed since last quarter; Brainz has covered how AI is reducing physician burnout while improving patient care. What it should never do is make the decision. That boundary is the whole design of the telehealth I practise.
How should a busy executive actually start?
Order the five numbers this month, privately if your system will not provide them. Put the results in front of a physician who will read all of them together, not one specialist per number. Decide the plan based on evidence: ApoB and Lp(a) set the intensity of lipid treatment, the calcium score settles the argument when the calculators disagree, home blood pressure sets the target, and fitness sets the training. Then measure again in a year. That is the entire method. It is unglamorous, it fits into a quarterly calendar, and it is what the best-informed cardiologists do for themselves.
If you want the version of this that travels with you across Europe, physician-led and built for people who do not have time to be patients, you can take a free two-minute health assessment with AETHERA Health. Every assessment is reviewed by an EU-licensed physician, and the Premium programme is designed around exactly these numbers.
Read more from Hilaryano Ferreira
Hilaryano Ferreira, Cardiologist & Founder of Aethera Health
Hilaryano Ferreira is a cardiologist and the founder of Aethera Health, an EU-licensed telehealth platform based in Portugal. The platform provides physician-led online care in weight management, cardiovascular health, men's and women's health, and longevity, supported by AI-assisted triage. He has over a decade of clinical practice. Besides founding Aethera, he works in cardiology and co-authored research published in EP Europace in 2021 on using artificial intelligence to automate remote follow-up of cardiac devices. That early work shaped the principle Aethera is built on: automation absorbs the administrative weight of medicine, while licensed physicians keep every clinical decision.
References:
2026 ACC/AHA Guideline on the Management of Dyslipidemia (Lp(a) once in a lifetime; ApoB; coronary artery calcium scoring, Class 1).
Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
Mandsager K et al. Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Netw Open. 2018;1:e183605.
Global Wellness Summit, Wellness Trends 2026.
